{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:18Z","timestamp":1791272358385,"version":"4.1.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:00:00Z","timestamp":1376352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/nrclinonc.2013.144","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T10:34:58Z","timestamp":1376390098000},"page":"616-624","source":"Crossref","is-referenced-by-count":88,"title":["Advances in the treatment of neurofibromatosis-associated tumours"],"prefix":"10.1038","volume":"10","author":[{"given":"Andrew L.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Gutmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,13]]},"reference":[{"key":"BFnrclinonc2013144_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/jnnp.2010.206532","volume":"10","author":"RE Ferner","year":"2010","unstructured":"Ferner, R. E. The neurofibromatoses. Pract. Neurol. 10, 82\u201393 (2010).","journal-title":"Pract. Neurol."},{"key":"BFnrclinonc2013144_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/jcb.21506","volume":"102","author":"SS Houshmandi","year":"2007","unstructured":"Houshmandi, S. S. & Gutmann, D. H. All in the family: using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors. J. Cell. Biochem. 102, 811\u2013819 (2007).","journal-title":"J. Cell. Biochem."},{"key":"BFnrclinonc2013144_CR3","first-page":"575","volume":"45","author":"DA Stumpf","year":"1987","unstructured":"Stumpf, D. A. et al. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 45, 575\u2013578 (1987).","journal-title":"Arch. Neurol."},{"key":"BFnrclinonc2013144_CR4","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","volume":"59","author":"ME Baser","year":"2002","unstructured":"Baser, M. E. et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59, 1759\u20131765 (2002).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","volume":"151","author":"SA Rasmussen","year":"2000","unstructured":"Rasmussen, S. A. & Friedman, J. M. NF1 gene and neurofibromatosis 1. Am. J. Epidemiol. 151, 33\u201340 (2000).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc2013144_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/jmg.26.11.704","volume":"26","author":"SM Huson","year":"1989","unstructured":"Huson, S. M., Compston, D. A., Clark, P. & Harper, P. S. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J. Med. Genet. 26, 704\u2013711 (1989).","journal-title":"J. Med. Genet."},{"key":"BFnrclinonc2013144_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DG Evans","year":"2005","unstructured":"Evans, D. G. et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol. Neurotol. 26, 93\u201397 (2005).","journal-title":"Otol. Neurotol."},{"key":"BFnrclinonc2013144_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans, D. G. et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am. J. Med. Genet. A 152A, 327\u2013332 (2010).","journal-title":"Am. J. Med. Genet. A"},{"key":"BFnrclinonc2013144_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/humu.9245","volume":"23","author":"A De Luca","year":"2004","unstructured":"De Luca, A. et al. Novel and recurrent mutations in the NF1 gene in Italian patients with neurofibromatosis type 1. Hum. Mutat. 23, 629 (2004).","journal-title":"Hum. Mutat."},{"key":"BFnrclinonc2013144_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/jmg.2009.070342","volume":"46","author":"DG Evans","year":"2009","unstructured":"Evans, D. G. & Wallace, A. An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). J. Med. Genet. 46, 792 (2009).","journal-title":"J. Med. Genet."},{"key":"BFnrclinonc2013144_CR11","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/320121","volume":"68","author":"SA Rasmussen","year":"2001","unstructured":"Rasmussen, S. A., Yang, Q. & Friedman, J. M. Mortality in neurofibromatosis 1: an analysis using U. S. death certificates. Am. J. Hum. Genet. 68, 1110\u20131118 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrclinonc2013144_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","volume":"49","author":"A Wilding","year":"2012","unstructured":"Wilding, A. et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J. Med. Genet. 49, 264\u2013269 (2012).","journal-title":"J. Med. Genet."},{"key":"BFnrclinonc2013144_CR13","first-page":"197","volume":"36","author":"JM McGaughran","year":"1999","unstructured":"McGaughran, J. M. et al. A clinical study of type 1 neurofibromatosis in north west England. J. Med. Genet. 36, 197\u2013203 (1999).","journal-title":"J. Med. Genet."},{"key":"BFnrclinonc2013144_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","volume":"70","author":"JM Friedman","year":"1997","unstructured":"Friedman, J. M. & Birch, P. H. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am. J. Med. Genet. 70, 138\u2013143 (1997).","journal-title":"Am. J. Med. Genet."},{"key":"BFnrclinonc2013144_CR15","doi-asserted-by":"publisher","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","volume":"7","author":"SR Plotkin","year":"2012","unstructured":"Plotkin, S. R. et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7, e35711 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2013144_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans, D. G. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311\u2013314 (2002).","journal-title":"J. Med. Genet."},{"key":"BFnrclinonc2013144_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","volume":"125","author":"R Listernick","year":"1994","unstructured":"Listernick, R., Charrow, J., Greenwald, M. & Mets, M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J. Pediatr. 125, 63\u201366 (1994).","journal-title":"J. Pediatr."},{"key":"BFnrclinonc2013144_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0161-6420(84)34217-8","volume":"91","author":"RA Lewis","year":"1984","unstructured":"Lewis, R. A., Gerson, L. P., Axelson, K. A., Riccardi, V. M. & Whitford, R. P. von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 91, 929\u2013935 (1984).","journal-title":"Ophthalmology"},{"key":"BFnrclinonc2013144_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.59.5.759","volume":"59","author":"DH Gutmann","year":"2002","unstructured":"Gutmann, D. H. et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59, 759\u2013761 (2002).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR20","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1002\/1097-0142(19931101)72:9<2746::AID-CNCR2820720936>3.0.CO;2-W","volume":"72","author":"I Matsui","year":"1993","unstructured":"Matsui, I. et al. Neurofibromatosis type 1 and childhood cancer. Cancer 72, 2746\u20132754 (1993).","journal-title":"Cancer"},{"key":"BFnrclinonc2013144_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJM199706123362404","volume":"336","author":"L Side","year":"1997","unstructured":"Side, L. et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med. 336, 1713\u20131720 (1997).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2013144_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/bjc.1994.431","volume":"70","author":"CA Stiller","year":"1994","unstructured":"Stiller, C. A., Chessells, J. M. & Fitchett, M. Neurofibromatosis and childhood leukaemia\/lymphoma: a population-based UKCCSG study. Br. J. Cancer 70, 969\u2013972 (1994).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc2013144_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0022-5347(05)68171-2","volume":"162","author":"MM Walther","year":"1999","unstructured":"Walther, M. M., Herring, J., Enquist, E., Keiser, H. R. & Linehan, W. M. von Recklinghausen's disease and pheochromocytomas. J. Urol. 162, 1582\u20131586 (1999).","journal-title":"J. Urol."},{"key":"BFnrclinonc2013144_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.amjmed.2012.07.022","volume":"126","author":"M Vlenterie","year":"2013","unstructured":"Vlenterie, M. et al. Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. Am. J. Med. 126, 174\u2013180 (2013).","journal-title":"Am. J. Med."},{"key":"BFnrclinonc2013144_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jpeds.2004.02.026","volume":"144","author":"L Sung","year":"2004","unstructured":"Sung, L. et al. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J. Pediatr. 144, 666\u2013668 (2004).","journal-title":"J. Pediatr."},{"key":"BFnrclinonc2013144_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jmg.2007.049346","volume":"44","author":"S Sharif","year":"2007","unstructured":"Sharif, S. et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J. Med. Genet. 44, 481\u2013484 (2007).","journal-title":"J. Med. Genet."},{"key":"BFnrclinonc2013144_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","volume":"178","author":"EM Jouhilahti","year":"2011","unstructured":"Jouhilahti, E. M. et al. The development of cutaneous neurofibromas. Am. J. Pathol. 178, 500\u2013505 (2011).","journal-title":"Am. J. Pathol."},{"key":"BFnrclinonc2013144_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2008.12.051","volume":"61","author":"KP Boyd","year":"2009","unstructured":"Boyd, K. P., Korf, B. R. & Theos, A. Neurofibromatosis type 1. J. Am. Acad. Dermatol. 61, 1\u201314 (2009).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrclinonc2013144_CR29","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/088307380201700808","volume":"17","author":"T Rosser","year":"2002","unstructured":"Rosser, T. & Packer, R. J. Neurofibromas in children with neurofibromatosis 1. J. Child. Neurol. 17, 585\u2013591 (2002).","journal-title":"J. Child. Neurol."},{"key":"BFnrclinonc2013144_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"CE Prada","year":"2012","unstructured":"Prada, C. E. et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J. Pediatr. 160, 461\u2013467 (2012).","journal-title":"J. Pediatr."},{"key":"BFnrclinonc2013144_CR31","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","volume":"57","author":"BS Ducatman","year":"1986","unstructured":"Ducatman, B. S., Scheithauer, B. W., Piepgras, D. G., Reiman, H. M. & Ilstrup, D. M. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57, 2006\u20132021 (1986).","journal-title":"Cancer"},{"key":"BFnrclinonc2013144_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/NEN.0b013e318165eb75","volume":"67","author":"FJ Rodriguez","year":"2008","unstructured":"Rodriguez, F. J. et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J. Neuropathol. Exp. Neurol. 67, 240\u2013249 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrclinonc2013144_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0022-3476(89)80137-4","volume":"114","author":"R Listernick","year":"1989","unstructured":"Listernick, R., Charrow, J., Greenwald, M. J. & Esterly, N. B. Optic gliomas in children with neurofibromatosis type 1. J. Pediatr. 114, 788\u2013792 (1989).","journal-title":"J. Pediatr."},{"key":"BFnrclinonc2013144_CR34","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0022-3476(95)70159-1","volume":"127","author":"R Listernick","year":"1995","unstructured":"Listernick, R., Darling, C., Greenwald, M., Strauss, L. & Charrow, J. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J. Pediatr. 127, 718\u2013722 (1995).","journal-title":"J. Pediatr."},{"key":"BFnrclinonc2013144_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M","volume":"89","author":"R Listernick","year":"1999","unstructured":"Listernick, R., Charrow, J. & Gutmann, D. H. Intracranial gliomas in neurofibromatosis type 1. Am. J. Med. Genet. 89, 38\u201344 (1999).","journal-title":"Am. J. Med. Genet."},{"key":"BFnrclinonc2013144_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0022-3476(95)70449-3","volume":"126","author":"R Habiby","year":"1995","unstructured":"Habiby, R., Silverman, B., Listernick, R. & Charrow, J. Precocious puberty in children with neurofibromatosis type 1. J. Pediatr. 126, 364\u2013367 (1995).","journal-title":"J. Pediatr."},{"key":"BFnrclinonc2013144_CR37","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1212\/WNL.45.10.1897","volume":"45","author":"PT Molloy","year":"1995","unstructured":"Molloy, P. T. et al. Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 45, 1897\u20131902 (1995).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR38","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1227\/01.NEU.0000298904.63635.2D","volume":"61","author":"NJ Ullrich","year":"2007","unstructured":"Ullrich, N. J., Raja, A. I., Irons, M. B., Kieran, M. W. & Goumnerova, L. Brainstem lesions in neurofibromatosis type 1. Neurosurgery 61, 762\u2013767 (2007).","journal-title":"Neurosurgery"},{"key":"BFnrclinonc2013144_CR39","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1212\/WNL.46.6.1652","volume":"46","author":"IF Pollack","year":"1996","unstructured":"Pollack, I. F., Shultz, B. & Mulvihill, J. J. The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 46, 1652\u20131660 (1996).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/PL00007285","volume":"16","author":"M Vinchon","year":"2000","unstructured":"Vinchon, M., Soto-Ares, G., Ruchoux, M. M. & Dhellemmes, P. Cerebellar gliomas in children with NF1: pathology and surgery. Childs Nerv. Syst. 16, 417\u2013420 (2000).","journal-title":"Childs Nerv. Syst."},{"key":"BFnrclinonc2013144_CR41","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.0.CO;2-#","volume":"79","author":"JM Maris","year":"1997","unstructured":"Maris, J. M. et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 79, 1438\u20131446 (1997).","journal-title":"Cancer"},{"key":"BFnrclinonc2013144_CR42","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","volume":"24","author":"S Sharif","year":"2006","unstructured":"Sharif, S. et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J. Clin. Oncol. 24, 2570\u20132575 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013144_CR43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajmg.1320520411","volume":"52","author":"DM Parry","year":"1994","unstructured":"Parry, D. M. et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am. J. Med. Genet. 52, 450\u2013461 (1994).","journal-title":"Am. J. Med. Genet."},{"key":"BFnrclinonc2013144_CR44","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/00006123-199605000-00004","volume":"38","author":"VF Mautner","year":"1996","unstructured":"Mautner, V. F. et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38, 880\u2013886 (1996).","journal-title":"Neurosurgery"},{"key":"BFnrclinonc2013144_CR45","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11\u201313, 1991. The Consensus Development Panel. Arch. Neurol. 51, 201\u2013207 (1994).","DOI":"10.1001\/archneur.1994.00540140115021"},{"key":"BFnrclinonc2013144_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/00005072-199303000-00002","volume":"52","author":"RA Sobel","year":"1993","unstructured":"Sobel, R. A. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J. Neuropathol. Exp. Neurol. 52, 106\u2013113 (1993).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrclinonc2013144_CR47","first-page":"92","volume":"33","author":"VF Mautner","year":"1993","unstructured":"Mautner, V. F., Tatagiba, M., Guthoff, R., Samii, M. & Pulst, S. M. Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33, 92\u201396 (1993).","journal-title":"Neurosurgery"},{"key":"BFnrclinonc2013144_CR48","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri, A. R. et al. Neurofibromatosis type 2. Lancet 373, 1974\u20131986 (2009).","journal-title":"Lancet"},{"key":"BFnrclinonc2013144_CR49","first-page":"603","volume":"84","author":"DG Evans","year":"1992","unstructured":"Evans, D. G. et al. A clinical study of type 2 neurofibromatosis. Q. J. Med. 84, 603\u2013618 (1992).","journal-title":"Q. J. Med."},{"key":"BFnrclinonc2013144_CR50","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","volume":"64","author":"M MacCollin","year":"2005","unstructured":"MacCollin, M. et al. Diagnostic criteria for schwannomatosis. Neurology 64, 1838\u20131845 (2005).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1086\/513207","volume":"80","author":"TJ Hulsebos","year":"2007","unstructured":"Hulsebos, T. J. et al. Germline mutation of INI1\/SMARCB1 in familial schwannomatosis. Am. J. Hum. Genet. 80, 805\u2013810 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrclinonc2013144_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ajmg.a.35760","volume":"161","author":"SR Plotkin","year":"2013","unstructured":"Plotkin, S. R. et al. Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria. Am. J. Med. Genet. A 161, 405\u2013416 (2013).","journal-title":"Am. J. Med. Genet. A"},{"key":"BFnrclinonc2013144_CR53","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3171\/jns.1997.87.4.0610","volume":"87","author":"J Antinheimo","year":"1997","unstructured":"Antinheimo, J. et al. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J. Neurosurg. 87, 610\u2013614 (1997).","journal-title":"J. Neurosurg."},{"key":"BFnrclinonc2013144_CR54","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2214\/ajr.165.4.7676998","volume":"165","author":"VF Mautner","year":"1995","unstructured":"Mautner, V. F. et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am. J. Roentgenol. 165, 951\u2013955 (1995).","journal-title":"AJR Am. J. Roentgenol."},{"key":"BFnrclinonc2013144_CR55","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1440-1789.2012.01306.x","volume":"32","author":"C Hagel","year":"2012","unstructured":"Hagel, C. et al. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology 32, 611\u2013616 (2012).","journal-title":"Neuropathology"},{"key":"BFnrclinonc2013144_CR56","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3171\/2010.11.SPINE10350","volume":"14","author":"SR Plotkin","year":"2011","unstructured":"Plotkin, S. R. et al. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J. Neurosurg. Spine 14, 543\u2013547 (2011).","journal-title":"J. Neurosurg. Spine"},{"key":"BFnrclinonc2013144_CR57","first-page":"1649","volume":"151","author":"AO Stemmer-Rachamimov","year":"1997","unstructured":"Stemmer-Rachamimov, A. O. et al. Universal absence of merlin, but not other ERM family members, in schwannomas. Am. J. Pathol. 151, 1649\u20131654 (1997).","journal-title":"Am. J. Pathol."},{"key":"BFnrclinonc2013144_CR58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/modpathol.3880513","volume":"15","author":"N Kimura","year":"2002","unstructured":"Kimura, N. et al. Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen's disease. Mod. Pathol. 15, 183\u2013188 (2002).","journal-title":"Mod. Pathol."},{"key":"BFnrclinonc2013144_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/gcc.2870100109","volume":"10","author":"DH Gutmann","year":"1994","unstructured":"Gutmann, D. H., Cole, J. L., Stone, W. J., Ponder, B. A. & Collins, F. S. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosomes Cancer 10, 55\u201358 (1994).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrclinonc2013144_CR60","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","volume":"62","author":"GF Xu","year":"1990","unstructured":"Xu, G. F. et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62, 599\u2013608 (1990).","journal-title":"Cell"},{"key":"BFnrclinonc2013144_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/347291a0","volume":"347","author":"AM Buchberg","year":"1990","unstructured":"Buchberg, A. M., Cleveland, L. S., Jenkins, N. A. & Copeland, N. G. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 347, 291\u2013294 (1990).","journal-title":"Nature"},{"key":"BFnrclinonc2013144_CR62","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/356713a0","volume":"356","author":"TN Basu","year":"1992","unstructured":"Basu, T. N. et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356, 713\u2013715 (1992).","journal-title":"Nature"},{"key":"BFnrclinonc2013144_CR63","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761\u2013774 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc2013144_CR64","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","volume":"63","author":"R Ballester","year":"1990","unstructured":"Ballester, R. et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851\u2013859 (1990).","journal-title":"Cell"},{"key":"BFnrclinonc2013144_CR65","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","volume":"63","author":"GA Martin","year":"1990","unstructured":"Martin, G. A. et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63, 843\u2013849 (1990).","journal-title":"Cell"},{"key":"BFnrclinonc2013144_CR66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","volume":"69","author":"JE DeClue","year":"1992","unstructured":"DeClue, J. E. et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69, 265\u2013273 (1992).","journal-title":"Cell"},{"key":"BFnrclinonc2013144_CR67","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/ng0296-144","volume":"12","author":"G Bollag","year":"1996","unstructured":"Bollag, G. et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12, 144\u2013148 (1996).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc2013144_CR68","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","volume":"65","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta, B., Yi, Y., Chen, D. Y., Weber, J. D. & Gutmann, D. H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 65, 2755\u20132760 (2005).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013144_CR69","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123, 340\u2013347 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc2013144_CR70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nn792","volume":"5","author":"J Tong","year":"2002","unstructured":"Tong, J., Hannan, F., Zhu, Y., Bernards, A. & Zhong, Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 5, 95\u201396 (2002).","journal-title":"Nat. Neurosci."},{"key":"BFnrclinonc2013144_CR71","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1523\/JNEUROSCI.23-26-08949.2003","volume":"23","author":"B Dasgupta","year":"2003","unstructured":"Dasgupta, B., Dugan, L. L. & Gutmann, D. H. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 23, 8949\u20138954 (2003).","journal-title":"J. Neurosci."},{"key":"BFnrclinonc2013144_CR72","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1523\/JNEUROSCI.3994-09.2010","volume":"30","author":"JA Brown","year":"2010","unstructured":"Brown, J. A., Gianino, S. M. & Gutmann, D. H. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J. Neurosci. 30, 5579\u20135589 (2010).","journal-title":"J. Neurosci."},{"key":"BFnrclinonc2013144_CR73","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau, G. A. et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363, 515\u2013521 (1993).","journal-title":"Nature"},{"key":"BFnrclinonc2013144_CR74","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter, J. A. et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72, 791\u2013800 (1993).","journal-title":"Cell"},{"key":"BFnrclinonc2013144_CR75","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nrc1213","volume":"3","author":"AI McClatchey","year":"2003","unstructured":"McClatchey, A. I. Merlin and ERM proteins: unappreciated roles in cancer development? Nat. Rev. Cancer 3, 877\u2013883 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc2013144_CR76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1534-5807(01)00009-0","volume":"1","author":"RJ Shaw","year":"2001","unstructured":"Shaw, R. J. et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 1, 63\u201372 (2001).","journal-title":"Dev. Cell"},{"key":"BFnrclinonc2013144_CR77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ncb1339","volume":"8","author":"F Hamaratoglu","year":"2006","unstructured":"Hamaratoglu, F. et al. The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 8, 27\u201336 (2006).","journal-title":"Nat. Cell Biol."},{"key":"BFnrclinonc2013144_CR78","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto, M., Cole, B. K., Lallemand, D., Liu, C. H. & McClatchey, A. I. Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin. J. Cell Biol. 177, 893\u2013903 (2007).","journal-title":"J. Cell Biol."},{"key":"BFnrclinonc2013144_CR79","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James, M. F. et al. NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell Biol. 29, 4250\u20134261 (2009).","journal-title":"Mol. Cell Biol."},{"key":"BFnrclinonc2013144_CR80","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bjps.2007.03.035","volume":"61","author":"SM Levine","year":"2008","unstructured":"Levine, S. M., Levine, E., Taub, P. J. & Weinberg, H. Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I. J. Plast. Reconstr. Aesthet. Surg. 61, 958\u2013962 (2008).","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"BFnrclinonc2013144_CR81","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson, K. A. et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 13, 1218\u20131224 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2013144_CR82","first-page":"1819","volume":"27","author":"VF Mautner","year":"2007","unstructured":"Mautner, V. F. et al. Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1. Anticancer Res. 27, 1819\u20131822 (2007).","journal-title":"Anticancer Res."},{"key":"BFnrclinonc2013144_CR83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdm450","volume":"19","author":"RE Ferner","year":"2008","unstructured":"Ferner, R. E. et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann. Oncol. 19, 390\u2013394 (2008).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc2013144_CR84","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11060-012-0840-5","volume":"108","author":"LL Tsai","year":"2012","unstructured":"Tsai, L. L. et al. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J. Neurooncol. 108, 469\u2013475 (2012).","journal-title":"J. Neurooncol."},{"issue":"Suppl. 4","key":"BFnrclinonc2013144_CR85","doi-asserted-by":"publisher","first-page":"A160","DOI":"10.1227\/01.NEU.0000337597.18599.D3","volume":"65","author":"K Karabatsou","year":"2009","unstructured":"Karabatsou, K., Kiehl, T. R., Wilson, D. M., Hendler, A. & Guha, A. Potential role of 18fluorodeoxyglucose-positron emission tomography\/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery 65 (Suppl. 4), A160\u2013A170 (2009).","journal-title":"Neurosurgery"},{"key":"BFnrclinonc2013144_CR86","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s00330-010-1862-z","volume":"20","author":"A Lakkaraju","year":"2010","unstructured":"Lakkaraju, A., Patel, C. N., Bradley, K. M. & Scarsbrook, A. F. PET\/CT in primary musculoskeletal tumours: a step forward. Eur. Radiol. 20, 2959\u20132972 (2010).","journal-title":"Eur. Radiol."},{"key":"BFnrclinonc2013144_CR87","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/COC.0b013e3181e9c08a","volume":"34","author":"VM Moretti","year":"2011","unstructured":"Moretti, V. M., Crawford, E. A., Staddon, A. P., Lackman, R. D. & Ogilvie, C. M. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am. J. Clin. Oncol. 34, 417\u2013421 (2011).","journal-title":"Am. J. Clin. Oncol."},{"key":"BFnrclinonc2013144_CR88","doi-asserted-by":"publisher","first-page":"756395","DOI":"10.1155\/2009\/756395","volume":"2009","author":"DE Porter","year":"2009","unstructured":"Porter, D. E. et al. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma 2009, 756395 (2009).","journal-title":"Sarcoma"},{"key":"BFnrclinonc2013144_CR89","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ana.410410204","volume":"41","author":"R Listernick","year":"1997","unstructured":"Listernick, R., Louis, D. N., Packer, R. J. & Gutmann, D. H. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann. Neurol. 41, 143\u2013149 (1997).","journal-title":"Ann. Neurol."},{"key":"BFnrclinonc2013144_CR90","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","volume":"15","author":"DG Evans","year":"2009","unstructured":"Evans, D. G. et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin. Cancer Res. 15, 5032\u20135039 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2013144_CR91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"DG Evans","year":"2005","unstructured":"Evans, D. G. et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br. J. Neurosurg. 19, 5\u201312 (2005).","journal-title":"Br. J. Neurosurg."},{"key":"BFnrclinonc2013144_CR92","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000156907","volume":"21","author":"J Rowe","year":"2008","unstructured":"Rowe, J., Radatz, M. & Kemeny, A. Radiosurgery for type II neurofibromatosis. Prog. Neurol. Surg. 21, 176\u2013182 (2008).","journal-title":"Prog. Neurol. Surg."},{"key":"BFnrclinonc2013144_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/jns.2001.94.1.0001","volume":"94","author":"JC Flickinger","year":"2001","unstructured":"Flickinger, J. C., Kondziolka, D., Niranjan, A. & Lunsford, L. D. Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods. J. Neurosurg. 94, 1\u20136 (2001).","journal-title":"J. Neurosurg."},{"key":"BFnrclinonc2013144_CR94","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin, S. R. et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol. Neurotol. 33, 1046\u20131052 (2012).","journal-title":"Otol. Neurotol."},{"key":"BFnrclinonc2013144_CR95","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrclinonc2013144_CR96","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis, M. A. et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 14, 1163\u20131170 (2012).","journal-title":"Neuro Oncol."},{"key":"BFnrclinonc2013144_CR97","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1158\/0008-5472.CAN-10-4558","volume":"71","author":"DA Mayes","year":"2011","unstructured":"Mayes, D. A. et al. Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res. 71, 4675\u20134685 (2011).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013144_CR98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ccr.2007.12.027","volume":"13","author":"J Wu","year":"2008","unstructured":"Wu, J. et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 13, 105\u2013116 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2013144_CR99","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.1068452","volume":"296","author":"Y Zhu","year":"2002","unstructured":"Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K. & Parada, L. F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296, 920\u2013922 (2002).","journal-title":"Science"},{"key":"BFnrclinonc2013144_CR100","first-page":"8573","volume":"63","author":"ML Bajenaru","year":"2003","unstructured":"Bajenaru, M. L. et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 63, 8573\u20138577 (2003).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013144_CR101","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1242\/dev.02162","volume":"132","author":"Y Zhu","year":"2005","unstructured":"Zhu, Y. et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 132, 5577\u20135588 (2005).","journal-title":"Development"},{"key":"BFnrclinonc2013144_CR102","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/0008-5472.236.65.1","volume":"65","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta, B., Li, W., Perry, A. & Gutmann, D. H. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 65, 236\u2013245 (2005).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013144_CR103","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","volume":"286","author":"K Cichowski","year":"1999","unstructured":"Cichowski, K. et al. Mouse models of tumor development in neurofibromatosis type 1. Science 286, 2172\u20132176 (1999).","journal-title":"Science"},{"key":"BFnrclinonc2013144_CR104","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1126\/science.286.5447.2176","volume":"286","author":"KS Vogel","year":"1999","unstructured":"Vogel, K. S. et al. Mouse tumor model for neurofibromatosis type 1. Science 286, 2176\u20132179 (1999).","journal-title":"Science"},{"key":"BFnrclinonc2013144_CR105","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1182\/blood-2003-08-2650","volume":"103","author":"DT Le","year":"2004","unstructured":"Le, D. T. et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103, 4243\u20134250 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc2013144_CR106","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini, M. et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14, 1617\u20131630 (2000).","journal-title":"Genes Dev."},{"key":"BFnrclinonc2013144_CR107","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1101\/gad.13.8.978","volume":"13","author":"M Giovannini","year":"1999","unstructured":"Giovannini, M. et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 13, 978\u2013986 (1999).","journal-title":"Genes Dev."},{"key":"BFnrclinonc2013144_CR108","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/onc.2010.609","volume":"30","author":"M Kalamarides","year":"2011","unstructured":"Kalamarides, M. et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 30, 2333\u20132344 (2011).","journal-title":"Oncogene"},{"key":"BFnrclinonc2013144_CR109","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1101\/gad.226302","volume":"16","author":"M Kalamarides","year":"2002","unstructured":"Kalamarides, M. et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 16, 1060\u20131065 (2002).","journal-title":"Genes Dev."},{"key":"BFnrclinonc2013144_CR110","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.neo.7900249","volume":"4","author":"DH Gutmann","year":"2002","unstructured":"Gutmann, D. H. & Giovannini, M. Mouse models of neurofibromatosis 1 and 2. Neoplasia 4, 279\u2013290 (2002).","journal-title":"Neoplasia"},{"key":"BFnrclinonc2013144_CR111","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1128\/MCB.22.14.5100-5113.2002","volume":"22","author":"ML Bajenaru","year":"2002","unstructured":"Bajenaru, M. L. et al. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell Biol. 22, 5100\u20135113 (2002).","journal-title":"Mol. Cell Biol."},{"key":"BFnrclinonc2013144_CR112","first-page":"129","volume":"17","author":"VM Riccardi","year":"1981","unstructured":"Riccardi, V. M. Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig. Artic. Ser. 17, 129\u2013145 (1981).","journal-title":"Birth Defects Orig. Artic. Ser."},{"key":"BFnrclinonc2013144_CR113","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pbc.23015","volume":"58","author":"J Wu","year":"2012","unstructured":"Wu, J. et al. Preclincial testing of sorafenib and RAD001 in the Nf(flox\/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr. Blood Cancer 58, 173\u2013180 (2012).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc2013144_CR114","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/0008-5472.CAN-07-5916","volume":"68","author":"B Hegedus","year":"2008","unstructured":"Hegedus, B. et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 68, 1520\u20131528 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013144_CR115","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cell.2013.01.053","volume":"152","author":"W Mo","year":"2013","unstructured":"Mo, W. et al. CXCR4\/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 152, 1077\u20131090 (2013).","journal-title":"Cell"},{"key":"BFnrclinonc2013144_CR116","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cub.2007.11.066","volume":"18","author":"CM Johannessen","year":"2008","unstructured":"Johannessen, C. M. et al. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 18, 56\u201362 (2008).","journal-title":"Curr. Biol."},{"key":"BFnrclinonc2013144_CR117","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1158\/0008-5472.CAN-09-3769","volume":"70","author":"NM Warrington","year":"2010","unstructured":"Warrington, N. M. et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res. 70, 5717\u20135727 (2010).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013144_CR118","doi-asserted-by":"publisher","first-page":"e39412","DOI":"10.1371\/journal.pone.0039412","volume":"7","author":"N Sabha","year":"2012","unstructured":"Sabha, N. et al. Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PLoS ONE 7, e39412 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2013144_CR119","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/neuonc\/noq012","volume":"12","author":"S Ammoun","year":"2010","unstructured":"Ammoun, S. et al. ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 12, 834\u2013843 (2010).","journal-title":"Neuro Oncol."},{"key":"BFnrclinonc2013144_CR120","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/13543784.2013.772979","volume":"22","author":"DH Gutmann","year":"2013","unstructured":"Gutmann, D. H., Blakeley, J. O., Korf, B. R. & Packer, R. J. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin. Investig. Drugs 22, 443\u2013462 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrclinonc2013144_CR121","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrclinonc2013144_CR122","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrclinonc2013144_CR123","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrclinonc2013144_CR124","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10689-005-0659-8","volume":"4","author":"ME Baser","year":"2005","unstructured":"Baser, M. E., Rai, H., Wallace, A. J. & Evans, D. G. Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation. Fam. Cancer 4, 321\u2013322 (2005).","journal-title":"Fam. Cancer"},{"key":"BFnrclinonc2013144_CR125","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1212\/WNL.59.2.290","volume":"59","author":"ME Baser","year":"2002","unstructured":"Baser, M. E. et al. Neurofibromatosis 2 and malignant mesothelioma. Neurology 59, 290\u2013291 (2002).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR126","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/00000478-199409000-00003","volume":"18","author":"JM Woodruff","year":"1994","unstructured":"Woodruff, J. M., Selig, A. M., Crowley, K. & Allen, P. W. Schwannoma (neurilemoma) with malignant transformation. A rare, distinctive peripheral nerve tumor. Am. J. Surg. Pathol. 18, 882\u2013895 (1994).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrclinonc2013144_CR127","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1212\/01.WNL.0000042321.94839.78","volume":"60","author":"A Gupta","year":"2003","unstructured":"Gupta, A., Cohen, B. H., Ruggieri, P., Packer, R. J. & Phillips, P. C. Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology 60, 130\u2013132 (2003).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR128","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/WNL.58.10.1461","volume":"58","author":"RJ Packer","year":"2002","unstructured":"Packer, R. J. et al. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 58, 1461\u20131470 (2002).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR129","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1200\/JCO.2005.03.8638","volume":"24","author":"BC Widemann","year":"2006","unstructured":"Widemann, B. C. et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J. Clin. Oncol. 24, 507\u2013516 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013144_CR130","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/01.wnl.0000243231.12248.67","volume":"67","author":"D Babovic-Vuksanovic","year":"2006","unstructured":"Babovic-Vuksanovic, D. et al. Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 67, 1860\u20131862 (2006).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR131","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2007.01.009","volume":"36","author":"D Babovic-Vuksanovic","year":"2007","unstructured":"Babovic-Vuksanovic, D. et al. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr. Neurol. 36, 293\u2013300 (2007).","journal-title":"Pediatr. Neurol."},{"key":"BFnrclinonc2013144_CR132","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/ajmg.a.33189","volume":"152A","author":"JL Kissil","year":"2010","unstructured":"Kissil, J. L. et al. What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am. J. Med. Genet. A 152A, 269\u2013283 (2010).","journal-title":"Am. J. Med. Genet. A"},{"issue":"Suppl.","key":"BFnrclinonc2013144_CR133","doi-asserted-by":"publisher","first-page":"e13601","DOI":"10.1200\/jco.2010.28.15_suppl.e13601","volume":"28","author":"BC Widemann","year":"2010","unstructured":"Widemann, B. C. et al. Phase II study of the mTOR inhibitor sirolimus for nonprogressive NF1-associated plexiform neurofibromas: a Neurofibromatosis Consortium study [abstract e13601]. J. Clin. Oncol. 28 (Suppl.), e13601 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013144_CR134","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/WNL.0b013e318207b031","volume":"76","author":"RI Jakacki","year":"2011","unstructured":"Jakacki, R. I. et al. Phase I trial of pegylated interferon-\u03b1-2b in young patients with plexiform neurofibromas. Neurology 76, 265\u2013272 (2011).","journal-title":"Neurology"},{"key":"BFnrclinonc2013144_CR135","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/pbc.24281","volume":"60","author":"A Kim","year":"2013","unstructured":"Kim, A. et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr. Blood Cancer 60, 396\u2013401 (2013).","journal-title":"Pediatr. Blood Cancer"},{"issue":"Suppl.","key":"BFnrclinonc2013144_CR136","doi-asserted-by":"crossref","first-page":"a9518","DOI":"10.1200\/jco.2006.24.18_suppl.9518","volume":"24","author":"KH Albritton","year":"2006","unstructured":"Albritton, K. H. et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST) [abstract]. J. Clin. Oncol. 24 (Suppl.), a9518 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"BFnrclinonc2013144_CR137","first-page":"a10009","volume":"28","author":"S Schuetze","year":"2009","unstructured":"Schuetze, S. et al. Results of a sarcoma alliance for research through collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma [abstract]. J. Clin. Oncol. 28 (Suppl.), a10009 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2013144_CR138","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","volume":"12","author":"MK Koenig","year":"2012","unstructured":"Koenig, M. K. et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R. D. 12, 121\u2013126 (2012).","journal-title":"Drugs R. D."},{"key":"BFnrclinonc2013144_CR139","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1158\/0008-5472.CAN-07-6867","volume":"68","author":"CH Kwon","year":"2008","unstructured":"Kwon, C. H. et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 68, 3286\u20133294 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2013144_CR140","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccr.2005.07.004","volume":"8","author":"Y Zhu","year":"2005","unstructured":"Zhu, Y. et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8, 119\u2013130 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2013144_CR141","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF02738732","volume":"6","author":"AS Tischler","year":"1995","unstructured":"Tischler, A. S., Shih, T. S., Williams, B. O. & Jacks, T. Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocr. Pathol. 6, 323\u2013335 (1995).","journal-title":"Endocr. Pathol."},{"key":"BFnrclinonc2013144_CR142","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","volume":"13","author":"J Jongsma","year":"2008","unstructured":"Jongsma, J. et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 13, 261\u2013271 (2008).","journal-title":"Cancer Cell"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.144","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T20:57:06Z","timestamp":1688417826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,13]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFnrclinonc2013144"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2013.144","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,13]]}}}